Flucelvax Quadrivalent Approved for Broader Age Group

Tecentriq Granted New Indication for Non-Small Cell Lung Cancer
October 15, 2021
Bryant Ranch Prepack Recalls Mislabeled Muscle Relaxant
October 18, 2021
Tecentriq Granted New Indication for Non-Small Cell Lung Cancer
October 15, 2021
Bryant Ranch Prepack Recalls Mislabeled Muscle Relaxant
October 18, 2021

October 15, 2021 – The U.S. FDA has expanded the indication for Flucelvax® Quadrivalent (influenza vaccine) to prevent the flu (caused by influenza virus subtypes A and B) in individuals who at least six months of age.

  • Flucelvax Quadrivalent, which is manufactured by Seqirus, first received FDA approval in 2016 to prevent the flu in individuals who are at least four years old.
  • The recommended dosing for children six months through eight years of age is one or two 0.5mL intramuscular injections given by a healthcare provider. If two doses are used, they should be administered at least four weeks apart. For individuals at least nine years old, only a single 0.5mL dose should be given.